The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate ...

Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Metsera stock plunges after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 ...

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 ...

The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated ...

Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo ...

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer (NYSE: PFE) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare. It has developed many medicines over the years; ...

Having lost the battle for Metsera, the Danish company continues its fight in the world of anti-obesity drugs, competing with ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...